EPO and Schnyder corneal dystrophy: Although this patient was successfully managed by transfusion with “least incompatible” O Rh(D) Pos C- E- K- Fy(a-) pRBCs and aggressive medical management including immunosuppressive therapy, erythropoietin, and oral iron per current 2020 ASH clinical guidelines [10], additional measures may assist in the long-term care of SCD patients, who often have complex transfusion requirements.